澳優(01717.HK)配發7,000萬股收購海普諾凱餘下15%股權
澳優乳業(01717.HK)宣布,以配發7,000萬股的方式收購海普諾凱生物科技餘下15%股份,涉及8.96億元,並提前發放海普諾凱營養品剩餘股份。
澳優宣布,透過間接全資附屬公司澳優乳品持有海普諾凱生物科技85%股份,又指此次配發的7,000萬股中,將有2,000萬股股份與海普生物未來三年的業績確立對賭協議。
協議指,於2020年至2022年若海普生物淨利潤年均增長率高於30%,將獲得該2,000萬股股份;年均增長率為20%至30.0%,則將行使海普生物認購期權零成本收回1,000萬股股份;若平均增長率為20%或以下,澳優將有權零成本收回該2,000萬股。
另外,由於海普諾凱營養品2018及2019年平均增長率就已超過對賭協議設立三年平均增長率,因此決定提前發放協議中的佳貝艾特業務單元剩餘股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.